Semaglutide, sold under the brand names Wegovy and Ozempic, and tirzepatide are prescribed for weight management and treating type 2 diabetes by helping patients regulate blood sugar.

Anti-obesity injections may have smaller effects on weight loss in a real-world context compared to clinical trials, as ...

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk ...

A Cleveland Clinic study shows that semaglutide and tirzepatide—injectable GLP-1 drugs for obesity—produce smaller weight ...

A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study ...

Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...

(Reuters) -Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing ...